Právní předpis byl sestaven k datu 01.03.2017.
Zobrazené znění právního předpisu je účinné od 01.03.2017.
Nařízení vlády, kterým se mění nařízení vlády č. 463/2013 Sb., o seznamech návykových látek, ve znění nařízení vlády č. 243/2015 Sb.
46/2017 Sb.
46
XXXXXXXX XXXXX
xx xxx 15. xxxxx 2017, xxxxxx se xxxx xxxxxxxx xxxxx x. 463/2013 Xx., o xxxxxxxxx xxxxxxxxxx xxxxx, xx znění xxxxxxxx xxxxx č. 243/2015 Xx.
Xxxxx xxxxxxxx xxxxx §44c odst. 1 xxxxxx x. 167/1998 Xx., o xxxxxxxxxx xxxxxxx a o xxxxx některých xxxxxxx xxxxxx, ve xxxxx xxxxxx x. 273/2013 Xx.:
Xx. X
Xxxxxxxx xxxxx č. 463/2013 Sb., x xxxxxxxxx xxxxxxxxxx látek, ve xxxxx nařízení xxxxx x. 243/2015 Xx., xx mění xxxxx:
1. X tabulce xxxxxxx x. 3 xx xxx xxxxx, xx xxxxxx je xx xxxxxxx x názvem "Xxxxxxxxxxx xxxxxxxxxx název (XXX) v českém xxxxxx" xxxxxxx xxxxx "Xxxxxxxxxx", vkládá nový xxxxx, ve kterém xx xx xxxxxxx x názvem "Xxxxxxxxxxx xxxxxxxxxx xxxxx (INN) x xxxxxx xxxxxx" xxxxxxx slovo "Acryloylfentanyl" x xx xxxxxxx x xxxxxx "Chemický xxxxx xxxxx XXXXX" xx xxxxxxx xxxxx "X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxx-2-xxxxxx".
2. X tabulce xxxxxxx x. 3 xx xxx řádek, xx xxxxxx xx xx xxxxxxx s xxxxxx "Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) v xxxxxx xxxxxx" uvedeno xxxxx "Xxxxxxxxxxxxxxxx", xxxxxx xxxx xxxxx, ve xxxxxx xx ve xxxxxxx s názvem "Xxxxxxxxxxx nechráněný xxxxx (XXX) x českém xxxxxx" xxxxxxx xxxxx "Xxxxxxxxxxxxxx" x xx xxxxxxx s názvem "Xxxxxxxx xxxxx xxxxx XXXXX" je xxxxxxx xxxxx "X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxx".
3. Xxxxxxx x. 4 zní:
"Příloha x. 4 x xxxxxxxx xxxxx x. 463/2013 Sb.
Seznam č. 4 xxxxxxxxxxxxxx xxxxx
|
Xxxxxxxxxxx xxxxxxxxxx název (XXX) x xxxxxx jazyce / xxxxxx xxxxx |
Xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxxx další obecný xxxxx |
Xxxxxxxx xxxxx xxxxx XXXXX |
Xxxxxxxx |
|
XX-XXXXXXXX |
X-[(1X)-1-(xxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1(xxxxxxxxxxxxxxxx)-1X-xxxxxxx-3-xxxxxxxxxx |
||
|
XX-XXXXXXXX |
X-(1-xxxxx-3-xxxxxx-1-xxxxxxxx-2-xx)-1-(4-xxxxxxxxxxx)-1X-xxxxxxx-3-xxxxxxxxxx |
||
|
XXX-XXXXXXXX |
X-[1-(xxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxx]-1-(xxxxxxxxxxxxxxxx)-1X-xxxxxxx-3-xxxxxxxxxx |
||
|
XXX-XXXXXXXX |
X-(1-xxxxx-3,3-xxxxxxxx-1-xxxxxxxx-2-xx)-1-[(4-xxxxxxxxxx)xxxxxx] xxxxxxx-3-xxxxxxxxxx |
||
|
XXX-XXXXXX |
X-(1-xxxxx-3,3-xxxxxxxx-1-xxxxxxxx-2-xx)-1-xxxxxx-1X-xxxxxxx-3-xxxxxxxxxx |
||
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx}xxxxxxxx |
||
|
XX-2201 |
[1-(5-xxxxxxxxxxx)-1X-xxxxx-3-xx](xxxxxxxx-1-xx)xxxxxxxx |
||
|
XXX-XXXXXX |
xxxxxx (2X)-2-{[1-(xxxxxxxxxxxxxxxx)xxxxx-3-xxxxxxxx]xxxxx}-3-xxxxxxxxxxxxxx |
||
|
5-Xxxxxxxxxxxxxxxx |
5-XXX |
5-(2-xxxxxxxxxxx)xxxxx |
|
|
XXXXXXX |
X-(xxxxxxxxx-1-xx)-1-xxxxxx-1X-xxxxxxx-3 -xxxxxxxxxx |
XXX48 |
|
|
xx-XXX |
2-xxxxx-1-(4-xxxxxxxxxxxx) propan-1-on |
||
|
Methedron |
bk-PMMA |
1-(4-methoxyfenyl)-2-(methylamino)propan-1-on |
|
|
2-Brommethkathinon |
2-BMC |
(RS)-1-(2-bromfenyl)-2-methylaminopropan-1-on |
|
|
3-Brommethkathinon |
3-BMC |
(RS)-1-(3 -xxxxxxxxx)-2-xxxxxxxxxxxxxxxxx-1-xx |
|
|
4-Xxxxxxxxxxxxxxxx |
4-XXX |
(XX)-1-(4-xxxxxxxxx)-2-xxxxxxxxxxxxxxxxx-1-xx |
Xxxxxxxxx |
|
25X-XXXXx |
2-(4-xxxx-2,5-xxxxxxxxxxxxxx)-X-[(2-xxxxxxxxxxxx)xxxxxx]xxxxxxxxx |
Xxxxx-36 |
|
|
25X-XXXXx |
2-(4-xxxxx-2,5-xxxxxxxxxxxxxx)-X-[(2-xxxxxxxxxxxx)xxxxxx]xxxxxxxxx |
2X-X-XXXXx |
|
|
25X-XXXXx |
2-(4-xxx-2,5-xxxxxxxxxxxxxx)-X-[(2-xxxxxxxxxxxx)xxxxxx]xxxxxxxxx |
XXXXx-2X-X |
|
|
Xxxxx-Xxxxxxxxx |
(2X)-1-(4-xxxxxxxx[2,3-x][1]xxxxxxxxxx-8-xx)xxxxxx-2-xxxx |
||
|
Xxxxxxx |
xx-XXXX |
2-(xxxxxxxxxxx)-1-[3,4-(xxxxxxxxxxxxx)xxxxx)]xxxxx-1-xx |
X1 |
|
2-Xxxxxxxxxxxxxx |
2-XX |
1-(2-xxxxxxxxxx)xxxxxx-2-xxxx |
|
|
3-Xxxxxxxxxxxxxx |
3-XX |
1-(3-xxxxxxxxxx)xxxxxx-2-xxxx |
|
|
4-Xxxxxxxxxxxxxx |
4-XX |
1-(4-xxxxxxxxxx)xxxxxx-2-xxxx |
XXX |
|
2X-X |
2-(4-xxxxx-2,5-xxxxxxxxxxxxxx)xxxxx-1-xxxx |
||
|
2-Xxxxxxxxxxxxxxxxxx |
2-XXX |
1-(2-xxxxxxxxxx)-X-xxxxxxxxxxxx-2-xxxx |
|
|
3-Xxxxxxxxxxxxxxxxxx |
3-XXX |
1-(3-xxxxxxxxxx)-X-xxxxxxxxxxxx-2-xxxx |
|
|
4-Xxxxxxxxxxxxxxxxxx |
4-XXX |
1-(4-xxxxxxxxxx)-X-xxxxxxxxxxxx-2-xxxx |
x-XXX |
|
2-Xxxxxxxxxxxxxxxxx |
2-XXX |
1-(2-xxxxxxxxxx)-2-(xxxxxxxxxxx)xxxxxx-1-xx |
|
|
3 -Xxxxxxxxxxxxxxxxx |
3-XXX |
1-(3-xxxxxxxxxx)-2-(xxxxxxxxxxx)xxxxxx-1-xx |
|
|
4-Xxxxxxxxxxxxxxxxx |
4-XXX |
1-(4-xxxxxxxxxx)-2-(xxxxxxxxxxx)xxxxxx-1-xx |
Xxxxxxxxx |
|
Xxxxxxxxxxxxxxxxxxxxxxxx |
2X-X |
(4-xxx-2,5-xxxxxxxxxxxxxxxxx)xxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
2X-X-2 |
[4-(xxxxxxxxxxxxx)-2,5-xxxxxxxxxxxxxxxxx]xxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
2X-X-7 |
[4-(xxxxxxxxxxxxxx)-2,5-xxxxxxxxxxxxxxxxx]xxxx |
|
|
XX-47,497 |
2-[(1X,3X)-3-xxxxxxxxxxxxxxxxx]-5-(2-xxxxxxxxxxx-2-xx)xxxxx |
||
|
XXX-13 |
(xxxxxxxx-1-xx)[4-(xxxxxxxxx)xxxxxxxx-1-xx]xxxxxxxx |
XX-13 |
|
|
XXXX |
1,4-xxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
2-(xxxxxxxxxxx)-2-xxxxx-xxxxxxxxxxxx |
||
|
Xxxxxxxxxxxx-2-xxxxx fentanyl |
N-(2-fluorfenyl)-1-(2-fenylethyl)piperidin-4-amin |
||
|
Diethyltryptamin |
DET |
N,N-diethyl-N-[2-(indol-3-yl)ethyl]amin |
|
|
Dimethoxyamfetamin |
DMA |
(2RS)-1-(2,5-dimethoxyfenyl)propan-2-amin |
|
|
p-Methyl-4-methylaminorex |
4,4'-DMAR |
4-methyl-5-(4-methylfenyl)-4,5-dihydro-1,3-oxazol-2-amin |
p4-DMAR |
|
Dimethylheptyltetrahydrokanabinol |
DMHP |
3-(1,2-dimethylheptyl)-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-benzo[c] xxxxxxx-1-xx |
|
|
3,4-Xxxxxxxxxxxxxxxxxxx |
3,4-XXXX |
1-(3,4-xxxxxxxxxxxxx)-2-(xxxxxxxxxxx)xxxxxx-1-xx |
|
|
Xxxxxxxxxxxxxxxxx |
XXX |
X-[2-(xxxxx-3-xx)xxxxx]-X,X-xxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxx |
XXX |
(2XX)-1-(4-xxxx-2,5-xxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
2,5-Xxxxxxxxx-4-xxxxxxxxxxxxxx |
XXX |
1-(4-xxxxx-2,5-xxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxx |
XXXX |
(2XX)-1-(4-xxxxx-2,5-xxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
XXX, XXX |
(2XX)-1-(2,5-xxxxxxxxx-4-xxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
2,5-Xxxxxxxxx-4-xxxxxxxxxxxx |
XXX |
1-(4-xxx-2,5-xxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxx |
Xxxxxxx |
(2XX)-1-xxxxx-2-(xxxxxxxxxxx)xxxxxx-1-xx |
|
|
Xxxxxxxxxxxx |
(XX)-xxxxx 2-fenyl-2-piperidin-2-ylacetát |
||
|
2-Ethylmethkathinon |
2-EMC |
(RS)-2-methylamino-1-(2-ethylfenyl)propane-1-on |
|
|
3-Ethylmethkathinon |
3-EMC |
(RS)-2-methylamino-1-(3-ethylfenyl)propane-1-on |
|
|
4-Ethylmethkathinon |
4-EMC |
(RS)-2-methylamino-1-(4-ethylfenyl)propane-1-on |
|
|
Etryptamin |
3-(2-aminobutyl)indol |
||
|
2-Fluoramfetamin |
2-FA |
1-(2-fluorfenyl)propan-2-amin |
|
|
3-Fluoramfetamin |
3-FA |
1-(3-fluorfenyl)propan-2-amin |
|
|
4-Fluoramfetamin |
4-FA |
1-(4-fluorfenyl)propan-2-amin |
|
|
5F-ADBICA |
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluorpentyl)-1H-indol-3-karboxamid |
||
|
5F-APINACA |
5F-AKB48 |
N-(adamantan-1-yl)-1-(5-fluorpentyl)-1H-indazol-3-karboxamid |
|
|
5F-AMB-PINACA |
5F-AMB |
Methyl 2-({[1-(5-fluorpentyl)-1H-indazol-3-yl]karbonyl}amino)-3-methylbutanoát |
5F-AMP |
|
Fentanyl xxxxxxxxx analog |
N-fenyl-N-[1-(2-fenylethyl)-4-piperidinyl]-butanamid |
||
|
4-Fluor-butyrfentanyl |
4F-BF |
N-(4-fluorofenyl)-N-[(1-(2-fenylethyl)-4 piperidinyl)]butanamid |
|
|
4-Fluormetkathinon |
4-FMC |
1-(4-fluorfenyl)-2-(methylamino)propan-1-on |
Flefedron |
|
2-Fluormethamfetamin |
2-FMA |
(RS)-1-(2-fluorfenyl)-N-methylpropan-2-amin |
|
|
3-Fluormethamfetamin |
3-FMA |
(RS)-1-(3-fluorfenyl)-N-methylpropan-2-amin |
|
|
4-Fluormethamfetamin |
4-FMA |
(RS)-1-(4-fluorfenyl)-N-methylpropan-2-amin |
|
|
2-Fluormethkathinon |
2-FMC |
1-(2-fluorfenyl)-2-(methylamino)propan-1-on |
|
|
3-Fluormethkathinon |
3-FMC |
1-(3-fluorfenyl)-2-(methylamino)propan-1-on |
|
|
5F-MDMB-PINACA |
methyl (X)-2-({[1-(5-xxxxxxxxxxx)-1X-xxxxxxx-3-xx]xxxxxxxx}xxxxx)-3,3-xxxxxxxxxxxxxxxx |
||
|
5XXX-144 |
[1-(5-xxxxxxxxxxx)-1X-xxxxx-3-xx](2,2,3,3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx |
XXX-11 |
|
|
Xxxxxxxxxxxxxxx |
XX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxx-2-xxxxxxxxxx |
2-xxxxxxxxxxxxxxxx |
|
Xxxxxxxxxxxxxxxxxxx |
(2XX)-X-xxxxxxx-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
||
|
(xxx)Xxxxxxx-X-xxxxxxxx N-benzyl analog |
N-(1-benzylpiperidin-4-yl)-N-(4-fluorfenyl)-butanamid |
||
|
JWH-018 |
(naftalen-1-yl)(1-pentyl-1H-indol-3 -xx)xxxxxxxx |
||
|
XXX-073 |
(1-xxxxx-1X-xxxxx-3-xx)(xxxxxxxx-1-xx)xxxxxxxx |
||
|
XXX-081 |
(4-xxxxxxxxxxxxxxx-1-xx)(1-xxxxxx-1X-xxxxx-3-xx)xxxxxxxx |
||
|
XXX-122 |
(4-xxxxxxxxxxxxxx-1-xx)(1-xxxxxx- 1X-xxxxx-3-xx)xxxxxxxx |
||
|
XXX-200 |
[1-(2-xxxxxxxxxxxxxx)-1X-xxxxx-3-xx] (xxxxxxxx-1-xx)xxxxxxxx |
||
|
XXX-250 |
2-(2-xxxxxxxxxxxx)-1-(1-xxxxxx-1X-xxxxx-3-xx)xxxxx-1-xx |
||
|
XXX-398 |
(4-xxxxxxxxxxxxx-1-xx)(1-xxxxxx-1X-xxxxx-3-xx)xxxxxxxx |
||
|
Xxxxxxxx |
(2XX)-2-xxxxx-1-xxxxxxxxxxx-1-xx |
||
|
(+)-Xxxxxxxx |
XXX, XXX-25 |
(+)-8β-(3,3-xxxxxxxxxxxxxx)-6-xxxxxx-9,10-xxxxxxxxxxxxxxxx |
|
|
2-Xxxxxxxxxxxxxxx |
2-XX |
(2XX)-1-(2-xxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
3-Xxxxxxxxxxxxxxx |
3-XX |
(2XX)-1-(3 -xxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
4-Xxxxxxxxxxxxxxx |
4-XX |
(2XX)-1-(4-xxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
XXXX |
1-xxxxxx-4-xxxxxxxxxxxxxxx |
||
|
x-Xxxxxxxxxxxxxxxxxxx |
xXXX |
1-(3-xxxxxxxxxx)xxxxxxxxx |
|
|
Xxxxxxxxxxxx |
XXX |
(2XX)-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
XXXX |
5,6-(xxxxxxxxxxxxx)xxxxx-2-xxxx |
||
|
Xxxxxxxxxxxxxxxxx |
XXX, XXXX |
(2XX)-X-xxxxx-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxx |
xx-XXXX |
2-xxxxxxxxxx-1-(3,4-xxxxxxxxxxxxxxxxxx)xxxxxx-1-xx |
|
|
Xxxxxxxxxxxxxxxxxx |
XXXX |
(2XX)-X-xxxxxx-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
XXXX-XXXXXX |
X-[[1-(xxxxxxxxxxxxxxxx)-1X-xxxxx-3-xx]xxxxxxxx]-3-xxxxxx- xxxxxx, xxxxxx xxxxx |
||
|
XXXX-XXXXXXXX |
2-[[1-[(4-xxxxxxxxxx)xxxxxx]xxxxxxx-3-xxxxxxxx] xxxxx]-3,3- xxxxxxxx-xxxxxxxx |
||
|
3,4-Xxxxxxxxxxxxxxxxxxxxxxxx |
XXXX |
1-[3,4-(xxxxxxxxxxxxx)xxxxx]-2-(xxxxxxxxxx-1-xx)xxxxxx-1-xx |
XXXX |
|
2-Xxxxxxxxxxxxxxxxx |
2-XXX |
2-(xxxxxxxxxx)-1-(2-xxxxxxxxxxx)xxxxxx-1-xx |
|
|
3-Xxxxxxxxxxxxxxxxx |
3-XXX |
2-(xxxxxxxxxx)-1-(3-xxxxxxxxxxx)xxxxxx-1-xx |
|
|
4-Xxxxxxxxxxxxxxxxx |
4-XXX |
2-(xxxxxxxxxx)-1-(4-xxxxxxxxxxx)xxxxxx-1-xx |
|
|
4-Xxxxxxxxxxxxxxxxx |
Xxxxxxxx |
2-(xxxxxxxxxxx)-1-(4-xxxxxxxxxxx)xxxxxx-1-xx |
|
|
5-XxX-XXX |
5-xxxxxxx-α-xxxxxxxxxxxxxxx |
||
|
4-Xxxxxxxxxxxx xxxxxxxx |
4-XxX-XX |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx] xxxxxxxxx |
|
|
5-XxX-XXXX |
X-[2-(5-xxxxxxx-1X-xxxxx-3-xx)xxxxx]-X-(xxxx-2-xx-1-xx)xxxx-2-xx-1-xxxx |
||
|
3-Xxxxxxxxxxxxxxxxxx |
3-XxX-XXX |
1-[1-(3-xxxxxxx fenyl)cyklohexyl]piperidin |
|
|
Meskalin |
3,4,5-trimethoxyfenethylamin |
||
|
Methoxetamin |
MXE |
2-(ethylamino)-2-(3-methoxyfenyl)cyklohexanon |
|
|
Methylaminorex |
(±)-5-fenyl-4-methyl-4,5-dihydrooxazol-2-amin |
||
|
Methylon |
Bk-MDMA |
2-(methylamino)-1-[3,4-(methylendioxy)fenyl]propan-1-on |
|
|
2-Methylmetamfetamin |
2-MMA |
1-(2-methylfenyl)-N-methylpropan-2-amin |
|
|
3-Methylmetamfetamin |
3-MMA |
1-(3-methylfenyl)-N-methylpropan-2-amin |
|
|
2-Methylmetkathinon |
2-MMC |
2-(methylamino)-1-(2-methylfenyl)propan-1-on |
|
|
3-Methylmetkathinon |
3-MMC |
2-(methylamino)-1-(3-methylfenyl)propan-1-on |
|
|
Methoxytenamfetamin |
MMDA |
(2RS)-1-[5-methoxy-3,4-(methylendioxy)fenyl]propan-2-amin |
|
|
Methylthienylpropamin |
MPA |
N-methyl-1-(thiofen-2-yl)propan-2-amin |
|
|
MT-45 |
1-cyklohexyl-4-(1,2-difenylethyl)-piperazin |
||
|
2-Methylthioamfetamin |
2-MTA |
(2RS)-1-[2-(methylsulfanyl)fenyl]propan-2-amin |
|
|
3-Methylthioamfetamin |
3-MTA |
(2RS)-1-[3-(methylsulfanyl)fenyl]propan-2-amin |
|
|
4-Methylthioamfetamin |
4-MTA |
(2RS)-1-[4-(methylsulfanyl)fenyl]propan-2-amin |
|
|
Naftylpyrovaleron |
Nafyron |
1-(naftalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-on |
O-2482 |
|
OC xxxxxxxx |
X-3217 |
X-(2-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
X-Xxxxxxxxxxxxxxxxx |
XXX |
3-{-2-[(xxxxxxxxxxxxx)xxxxxx]-1-xxxxxxxxxxxxxxxxx} xxxxx |
|
|
Xxxxxxxxx |
3-xxxxx-6,6,9-xxxxxxxxx-7,8,9,10-xxxxxxxxxx-6X-xxxxx[x]xxxxxxx-1-xx |
||
|
Xxxxxxxxxxx |
XXX |
X-xxxxx-1-xxxxxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxx |
xxxxxxxxx |
1-xxxxx-2-(xxxxxxxxxxx)xxxxxx-1-xx |
|
|
x-Xxxxxxxxxxxxxxxxxxx |
xXXX |
1-(4-xxxxxxxxxx)xxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxx |
XXX |
(2XX)-1-(4-xxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
XXXX |
1-(4-xxxxxxxxxxxx)-X-xxxxxxxxxxxx-2-xxxx |
|
|
Xxxxxxxxxx |
3-[2-(xxxxxxxxxxxxx)xxxxx]-1X-xxxxx-4-xx-xxxxxxxxxx-xxxxxx |
||
|
Xxxxxxxx |
Xxxxxxxxx |
3-[2-(xxxxxxxxxxxxx)xxxxx]-1X-xxxxx-4-xx |
|
|
α-XXX |
2-(xxxxxxxxxx-1-xx)-1-(xxxxxxx-2-xx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxx |
XXX, PCPY |
1-(1-fenylcyklohexyl)pyrrolidin |
|
|
α -PVP |
1-fenyl-2-(pyrrolidin-1-yl)-1-pentan-1-on |
||
|
Salvinorin X |
Xxxxxxxxxx X |
xxxxxx-(2XX,4xX,6xX,7X,9XX,10xXX,10xX)-9-xxxxxxx-2-(xxxxx-3-xx)-6x,10x-xxxxxxxx-4,10-xxxxxxxxxxxxxxxx-1X-xxxxx[x]xxxxxxxxxx-7-xxxxxxxxxx |
|
|
Xxxxxxxxxxxx |
XXX |
1-[1-(2-xxxxxxx)xxxxxxxxxx]xxxxxxxxx |
|
|
1-(3-Xxxxxxxxxxxxxxxxxxx)xxxxxxxxx |
XXXXX |
1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
XXX |
X6x(10x)-, X6x(7)-, X7-, X8-, D10-, D9(11)-tetrahydrokanabinoly x xxxxxx stereoizomery |
|
|
Trimethoxyamfetamin |
TMA |
(2RS)-1-(3,4,5-tnmethoxyfenyl)propan-2-amin |
|
|
Trimethoxyamfetamin-2 |
TMA-2 |
(2RS)-1-(2,4,5-tnmethoxyfenyl)propan-2-amin |
|
|
UR-144 |
(1-pentyl-1H-indol-3-yl)-(2,2,3,3-tetramethylcyklopropyl)methanon |
TMCP-018 |
|
|
U-47700 |
3,4-dichlor-N-[2-(dimethylamino)cyklohexyl]-N-methylbenzamid |
||
|
W-15 |
4-chlor-N-(1-fenethylpiperidin-2-yliden)benzensulfonamid |
||
|
W-18 |
4-chlor-N-(1-[2-(4-nitrofenyl)ethyl]-piperidin-2-yliden)benzensulfonamid |
Včetně xxxxxxxxxxxxx xxxxxxxxxxxxxx látek, xx na výslovné xxxxxxx, xxxxxxxxx v xxxxx seznamu xx xxxxx xxxxxxxxx, xxx xxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx podle xxxxxxxxxx xxxxxxxxxx xxxxxxxx x xxxx xxxxxxxxxxxxxx látek xxxxxxxxx x xxxxx xxxxxxx xx xxxxx xxxxxxxxx, xxx xxxxx xxxxxxxxx.“.
4. X xxxxxxx xxxxxxx č. 5 xx pod řádek, xx xxxxxx xx xx xxxxxxx x xxxxxx "Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) v xxxxxx jazyce" xxxxxxx xxxxx "Xxxxxxxxxxx", xxxxxx xxxx xxxxx, ve xxxxxx xx xx xxxxxxx s xxxxxx "Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) v xxxxxx xxxxxx" uvedeno slovo "Xxxxxxxxx" x xx xxxxxxx x xxxxxx "Xxxxxxxx název podle XXXXX" je xxxxxxx xxxxx "1-xxxxx-2-xxxxxxxxx-xxx-2-xxxx".
5. X xxxxxxx xxxxxxx č. 5 se pod xxxxx, xx kterém xx xx xxxxxxx x xxxxxx "Xxxxxxxxxxx xxxxxxxxxx xxxxx (INN) x xxxxxx xxxxxx" xxxxxxx slovo "Levmetamfetamin", xxxxxx nový řádek, xx kterém je xx sloupci x xxxxxx "Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x xxxxxx jazyce" uvedeno xxxxx "Xxxxxxxxxxxxxxx" a xx xxxxxxx s xxxxxx "Chemický xxxxx xxxxx XXXXX" xx xxxxxxx slovo "(2S)-2,6-diamino-N-[(2S)-1-fenylpropan-2-yl]hexanamid".
6. X xxxxxxx přílohy x. 7 se xxx řádek, ve xxxxxx je xx xxxxxxx x xxxxxx "Xxxxxxxxxxx nechráněný xxxxx (XXX) x xxxxxx xxxxxx" xxxxxxx xxxxx "Xxxxxxxxxxxxxxx", xxxxxx nový xxxxx, ve kterém xx xx xxxxxxx x názvem "Mezinárodní xxxxxxxxxx název (XXX) x xxxxxx xxxxxx" xxxxxxx xxxxx "Fenazepam" x ve sloupci x xxxxxx "Xxxxxxxx xxxxx xxxxx XXXXX" xx xxxxxxx xxxxx "7-xxxxx-5-(2-xxxxxxxxxxx)-1,3-xxxxxxx-2X-1,4-xxxxxxxxxxxxx-2-xx".
7. X xxxxxxx xxxxxxx č. 7 xx xxxxx, xx xxxxxx xx xx xxxxxxx s názvem "Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x xxxxxx xxxxxx" xxxxxxx xxxxx "Xxxxxxxxx" x ve xxxxxxx x xxxxxx "Xxxxxxxx název xxxxx XXXXX" xx xxxxxxx xxxxx "2-fenyl-1,1-dimethylethylamin", xxxxxxx.
Xx. XX
Xxxx xxxxxxxx xxxx xxxxxxxx x xxxxxxx se xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) 2015/1535 xx xxx 9. xxxx 2015 o xxxxxxx xxx poskytování xxxxxxxxx x xxxxxxx xxxxxxxxxxx předpisů x xxxxxxxx xxx xxxxxx xxxxxxxxxx společnosti.
Čl. XXX
Xxxxxxxx
Xxxx nařízení xxxxxx účinnosti dnem 1. března 2017, x výjimkou čl. I xxxx 4, 5 x 7, xxxxx xxxxxxxx xxxxxxxxx dnem 1. května 2017.
&xxxx;Xxxxxxxx xxxxx:
Xxx. Sobotka v. x.
&xxxx;Xxxxxxx xxxxxxxxxxxxx:
XXXx. Xxx. Xxxxxx, XXX, x. x.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 44/2017 Sb. nabyl xxxxxxxxx dnem 1.3.2017, x xxxxxxxx čl. I xxxx 4, 5 x 7, které xxxxxxxx xxxxxxxxx 1.5.2017.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních předpisů x odkazech xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu.